Advanced Filters
noise

Viral Infections Clinical Trials

A listing of Viral Infections medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 541 clinical trials
W Wei Lyu, MD

Gut and Vaginal Microbiota Profile Study for HIV Women

Women Living with HIV Infection (WLHIV)are intended to acquire HPV infection which usually contributes to variable cervical lesions. we hypothesize that vaginal microbiota imbalance may make WLHIV prone to HPV infection,thereafter results in severe cervical lesion.

14 years of age Female Phase N/A

Frailty in Older HIV-infected Individuals

Frailty has been proposed as a measure of biological (as opposed to chronological) aging. In this study the investigators plan to: (1) measure frailty in a cohort of older HIV-infected individuals in Hong Kong, and its association with mortality and quality of life; (2) identify risk factors predictive of development …

50 years of age All Phase N/A

Evolution of HIV Reservoir, Inflammation and Microbiota Footprint of PLWH Switching to Long-acting Injectable Treatment Compared to Patients on Oral Dual or Triple Anti-integrase-based Therapy

In the last 40 years of HIV history, we have managed to attain most of our therapeutic objectives, namely virological suppression of most patients and sufficient immune reconstitution. Still, immune activation and inflammation persist and even if they decrease on ART (AntiRetroviral Treatment), they do not disappear and may be …

18 years of age All Phase N/A

Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV

Analysis of gut microbiota becomes more and more accessible in recent years. Experimental data in both animal and human studies have demonstrated that imbalance of the gut microbiota which is called symbiosis may participate in an accelerated procedure of ageing as well as the expression of frailty phenotype. People living …

55 years of age All Phase N/A

Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV

Combination antiretroviral therapy (cART) blocks intracellular human immunodeficiency virus (HIV) replication in CD4+ T-lymphocytes, but fails to eliminate latent HIV infected CD4+ T-lymphocytes. About 7 (range <1-100) in 106 of these cells are latently infected and can cause reactivation of proviral HIV when cART is stopped. These latently infected cells …

18 years of age All Phase N/A

AURORA Study-A Transformative Approach to Support PrEP Medication Persistence

This study is designed to test the hypothesis that, compared to oral PrEP, use of CAB-LA in underserved populations in a real-world setting supported by a digital health companion program will be associated with greater medication adherence, persistence, retention-in-care, and improved PROs. Patients in the study will receive current standard …

18 years of age All Phase N/A
E Edmundo Huerta Patricio, M.Biol.Sc.

Antiretroviral Speed Access Program

Migrant populations represent an increasing proportion of newly referred people living with HIV in Canada, particularly in Quebec. Timely HIV care of newly referred patients has important individual-level health benefits that can result in decreased transmission and benefit the society as a whole. Yet, the timing of events in the …

18 years of age All Phase N/A
E Elizabeth Mainwaring

HIV and Changes in the Gut Microbiome After Changes in Antiretroviral Therapy (ART)

This is a study that aims to contribute to the understanding of how antiretroviral therapy effects the gut microbiome which, if known, could inform decisions about drug choices at an individual level. The gut health is extremely important for all aspects of a persons wellbeing both at the level of …

18 years of age All Phase N/A
R Roland Tubiana, MD

Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV

Main objective is: To characterize the evolution of the immuno-virological profile of circulating blood cells and immune aging in patients who had participated to TEMPO-1 in 2007-2008 To evaluate the role of immune aging and inflammatory profile in the occurrence of comorbidities in HIV-infected individuals over a 15-year period The …

18 years of age All Phase N/A
A Axel URSENBACH, MD

Evaluation of Intermittent Triple Therapies in Real Life

The strategy of intermittent triple therapy for people living with HIV was validated in France following the randomized clinical trial QUATUOR. There is little data in real life, as shown in the meta-analysis of Parienti JJ et al. Currently this strategy is proposed by some teams in France, but is …

18 years of age All Phase N/A

Simplify language using AI